Molecular mechanisms and treatment strategies for methamphetamine‑induced neurodegeneration, inflammation and neurotoxicity.


Journal

Acta neurobiologiae experimentalis
ISSN: 1689-0035
Titre abrégé: Acta Neurobiol Exp (Wars)
Pays: Poland
ID NLM: 1246675

Informations de publication

Date de publication:
28 Dec 2023
Historique:
received: 28 12 2023
medline: 15 1 2024
pubmed: 15 1 2024
entrez: 15 1 2024
Statut: epublish

Résumé

Methamphetamine (METH) is a highly addictive psychostimulant known for its profound impact on the nervous system. Chronic METH use leads to neurotoxicity characterized by various molecular and structural alterations in the brain. This review article primarily aims to elucidate the mechanisms underlying METH‑induced neurotoxicity. METH's mechanism of action involves the inhibition of dopamine, serotonin, and norepinephrine reuptake, resulting in altered synaptic function. Prolonged METH exposure triggers oxidative stress, endoplasmic reticulum stress, mitochondrial dysfunction, impaired axonal transport, autophagy, and programmed cell death, ultimately contributing to neurotoxicity. These neurotoxic effects manifest as increased neuronal firing rate, disruptions in intracellular ion balance (Ca2+ and Na+), energy production imbalances, and excessive reactive oxygen species production. The blood‑brain barrier is compromised, leading to structural, functional, and neurochemical alterations, particularly in the fronto‑striatal circuit. While our comprehensive review addresses these intricate molecular and structural changes induced by METH, we also examined the latest therapeutic strategies designed to mitigate neurotoxicity. Our investigation sheds light on the critical need to comprehend the complex pathways underlying METH‑induced neurotoxicity and develop effective treatment approaches.

Identifiants

pubmed: 38224280
doi: 10.55782/ane-2023-2488
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

414-431

Auteurs

Samareh Omidvari (S)

Hearing Disorders Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. e@d.e.

Zahra Azimzadeh (Z)

Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. e@d.e.

Fariborz Rashnoo (F)

Department of General Surgery, School of Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. e@d.e.

Foozhan Tahmasebinia (F)

Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. e@d.e.

Aliasghar Keramatinia (A)

Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. e@d.e.

Navid Ahmady Roozbahany (NA)

Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. e@d.e.

Hojjat Allah Abbaszadeh (HA)

Hearing Disorders Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Dr.Abbaszadeh@sbmu.ac.ir.

Shahram Darabi (S)

Cellular and Molecular Research Center, Research Institute for Non‑Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran. e@d.e.

Classifications MeSH